Enanta Pharmaceuticals (ENTA) Stock Statistics & Valuation Metrics

Enanta Pharmaceuticals has a market cap or net worth of $413.51M. The enterprise value is $340.95M.

Enanta Pharmaceuticals has 29,018,522 shares outstanding. The number of shares has decreased by -2.65% in one year.

Enanta Pharmaceuticals’s return on equity (ROE) is -1.27 and return on invested capital (ROIC) is -31.08%.

The current PE Ratio of Enanta Pharmaceuticals is ―. Enanta Pharmaceuticals’s PEG ratio is 0.10.

In the last 12 months, Enanta Pharmaceuticals had revenue of 65.32M and earned -81.89M in profits. Earnings per share was -3.84.

In the last 12 months, operating cash flow was -14.17M and capital expenditures -4.29M, giving a free cash flow of -18.46M billion.

Enanta Pharmaceuticals pays an annual dividend of ―, resulting in a dividend yield of ―

Enanta Pharmaceuticals upcoming earnings date is May 11, 2026, After Close (Confirmed).

Enanta Pharmaceuticals as a current ratio of 4.21, with Debt / Equity ratio of 45.08%

In the past 12 months, Enanta Pharmaceuticals has paid -1.66M in taxes.

Enanta Pharmaceuticals EV to EBITDA ratio is -5.99, with an EV/FCF ratio of -13.19.

Enanta Pharmaceuticals has $185.85M in cash and marketable securities with $57.07M in debt, giving a net cash position of $128.78M billion.

Gross margin is 72.21%, with operating margin of -130.65%, and net profit margin of -125.36%.

The average price target for Enanta Pharmaceuticals is $18.50, which is 11.43% higher than the current price. The consensus rating is Moderate Buy